Clinical trial
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor…
NCT00411788 · Yale University, Other · Completed
Key facts
| NCT number | NCT00411788 |
|---|---|
| Title | A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer |
| Official title | A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer |
| Lead sponsor | Yale University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Rapamycin, Trastuzumab |
| Enrollment | 11 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Dec 15, 2006 |
| Last update posted | Sep 21, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: